Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs.
There's been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech – TargED Biopharmace
Boehringer Ingelheim's latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme
Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic st
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.